title: [The effect of pinyangmycin, dexamethasonum and sodium morrhuate injected concomitantly to treat cavernous hemangioma].
abstract: OBJECTIVE
  The effect of Pinyangmycin, Dexamethasonum and Sodium Morrhuate injected concomitantly to treat cavernous hemangioma in oral and maxillofacial regions was evaluated.
  
  
  METHODS
  The medical records of 350 patients with cavernous hemangioma in oral and maxillofacial regions between January 1998 and January 2002 were reviewed. One hundred and sixty-five of the patients were men, and 185 were women, the sex ratio was 1:1.12. The patients' ages were between 4 months and 55 years. Two hundred and Twenty-six hemangiomas were located in the maxillofacial regions, and 124 located in the oral cavity. The size of the lesions varied from 1 cm x 1 cm to 6 cm x 9 cm. Pinyangmycin, Dexamethasonum and Sodium Morrhuate were injected simultaneously into the lesions or in the vicinity of the cavernous hemangiomas, and the injection might be repeated every 5 to 7 days when necessary, and this process could be repeated 3 to 5 times.
  
  
  RESULTS
  Three hundred and fifty patients were followed up for 6-48 months. The cure and essentially cured rates were 95.48%, the total efficiency rate was 100%.
  
  
  CONCLUSIONS
  This method was a safe, simple and effective therapy to manage cavernous hemangioma in the oral and maxillofacial regions.
authors.forename: Bo-quan
authors.initials: BQ
authors.lastname: Shou
authors.forename: Wei-dong
authors.initials: WD
authors.lastname: Shou
authors.forename: Zhao-ye
authors.initials: ZY
authors.lastname: Meng
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yang
authors.forename: Sen-lin
authors.initials: SL
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000008:administration & dosage*; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006392:Hemangioma, Cavernous / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007267:Injections; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D012976:Sodium Morrhuate / Q000008:administration & dosage*
chemical_list: D001761:Bleomycin; C021771:zhengguangmycin; D003907:Dexamethasone; D012976:Sodium Morrhuate